Peripheral Vascular Disease (PVD) — HCC Risk Adjustment Focus — Clinical Documentation Guide (2026)

This guide focuses on Peripheral Vascular Disease (PVD) within the Medicare Advantage risk adjustment (HCC v28) context, with deep CDI query templates and RADV audit preparation. For a comprehensive clinical overview of PVD including pathophysiology, diagnostics, and full procedural coding, see the companion PVD Clinical Documentation Guide.

🔍 Definition

Peripheral Vascular Disease (PVD) is a broad term encompassing circulatory disorders affecting blood vessels outside the heart and brain — most commonly atherosclerotic narrowing or occlusion of the peripheral arteries supplying the lower and upper extremities. In the risk adjustment context, PVD coding specificity is critical: the difference between an unspecified PVD code and a highly specific atherosclerosis-with-gangrene code can represent hundreds of dollars per member per month in CMS Medicare Advantage risk adjustment payments.

Under CMS-HCC Model V28 (100% operative as of January 1, 2026), PVD conditions distribute across two primary HCC categories with distinct relative factor (RF) weights:

• HCC 263 — Atherosclerosis of Arteries of the Extremities with Ulceration or Gangrene: RF 1.118 (community, non-dual, aged)
• HCC 264 — Vascular Disease with Complications (includes atherosclerosis with rest pain, thrombosis, embolism): RF 0.455

Crucially, intermittent claudication alone (I70.211–I70.219) no longer maps to a payment HCC under V28, representing a significant shift from V24 where it contributed to HCC 107. Capturing the highest clinically supported specificity — rest pain, ulceration, or gangrene — is now essential to secure RAF credit for the documented disease burden.

🗂️ Alternative Terminology

🩺 Signs & Symptoms

Symptom severity corresponds directly to the appropriate ICD-10-CM code and HCC category. AHA research confirms ICD-10 codes accurately distinguish claudication versus CLTI with 81% sensitivity and 82% specificity when documentation is specific.

• Intermittent claudication — cramping, aching, or fatigue in calf, thigh, or buttock with exertion; resolves with rest. Corresponds to I70.21x. Note: no RAF credit in V28 alone.
• Rest pain — persistent burning or aching pain in foot or toes at rest, especially nocturnal; relieved by dependency. Corresponds to I70.22x (HCC 264, RF 0.455).
• Non-healing ulceration — ischemic ulcer at pressure points, toes, or heel; punched-out appearance, pale base, minimal bleeding. Corresponds to I70.23x–I70.25x (HCC 263, RF 1.118).
• Gangrene — dry or wet necrosis, blackened digits or foot. Corresponds to I70.26x (HCC 263, RF 1.118).
• Diminished or absent pedal pulses, bruits over femoral/popliteal arteries
• Dependent rubor, pallor on elevation, prolonged capillary refill
• Hair loss on lower extremity, shiny atrophic skin, muscle atrophy
• Ankle-Brachial Index (ABI): >1.4 non-compressible (media calcification), 0.9–1.4 normal, 0.70–0.89 mild PAD, 0.40–0.69 moderate PAD, <0.40 severe PAD/CLTI

🧭 Differential Diagnosis

📋 Clinical Indicators for Coders/CDI

Clinical indicators that should trigger CDI review and potential code specificity escalation in PVD cases:

🦴 Anatomy & Pathophysiology

PVD in the risk adjustment context is primarily driven by atherosclerosis of the peripheral arteries — a chronic, progressive inflammatory disease in which cholesterol plaques accumulate in the intima of medium and large vessels, progressively narrowing the lumen and reducing perfusion to distal tissues.

Vascular territory affected — ICD-10-CM I70.2xx governs atherosclerosis of native arteries of the extremities. The aortoiliac segment (Leriche syndrome), femoral-popliteal segment, and tibial/peroneal arteries each carry distinct procedural and documentation implications. I70.3xx–I70.7xx govern bypass graft disease (autologous vein, nonautologous biological, nonbiological, other).

Disease progression spectrum (Fontaine Classification → ICD-10-CM mapping):

• Stage I — Asymptomatic: ABI <0.9 without symptoms. Coded as I70.209 (atherosclerosis of native arteries, unspecified extremity, no ulceration/rest pain). No V28 RAF.
• Stage IIa/IIb — Claudication: I70.211–I70.219. No V28 RAF.
• Stage III — Rest pain (CLTI, formerly CLI): I70.221–I70.229. HCC 264, RF 0.455.
• Stage IV — Tissue loss (ulceration/gangrene) (CLTI): I70.231–I70.269. HCC 263, RF 1.118.

Pathophysiology of CLTI / Critical Limb Ischemia — Chronic Limb-Threatening Ischemia (CLTI) represents the severe end of the PAD spectrum, characterized by inadequate perfusion to sustain tissue viability at rest. As of ICD-10-CM FY2020+ and confirmed for FY2026, CLTI and Critical Limb Ischemia (CLI) are recognized as equivalent terms, indexed directly to the I70 category codes involving rest pain, ulceration, and gangrene.

Diabetic macroangiopathy — In diabetic patients, accelerated atherosclerosis affects tibial and peroneal vessels disproportionately, often producing CLTI without proximal disease. The coding pathway differs: E11.51 (diabetic peripheral angiopathy without gangrene) or E11.52 (with gangrene) captures the diabetes-attributable vascular damage. Additional I70.2xx codes may be coded separately per ICD-10-CM guidelines.

💊 Medication Impact / Treatment

Medications relevant to PVD affect both documentation and coding:

• Antiplatelet therapy — Aspirin, clopidogrel (Plavix), ticagrelor; first-line for symptomatic PAD per AHA/ACC PAD Guidelines; code long-term use Z79.82 (long-term use of aspirin), Z79.02 (long-term use of antithrombotics)
• Statins — Atorvastatin, rosuvastatin; mandatory in PAD for plaque stabilization; code long-term use Z79.899
• Cilostazol (Pletal) — Phosphodiesterase inhibitor; improves claudication distance; specific to claudication symptom management
• Vorapaxar (Zontivity) — PAR-1 antagonist; reduces MACE in established PAD
• Rivaroxaban (Vascular dose Xarelto) — COMPASS trial regimen (2.5 mg BID + aspirin) for high-risk PAD; code Z79.01 (long-term anticoagulant use)
• Antihypertensives / ACE inhibitors — HOPE trial data support ACE inhibition in PAD even without hypertension
• Wound care medications — In CLTI: topical antimicrobials, growth factors, negative pressure wound therapy (NPWT); document wound grade per WIfI classification
• Insulin / oral antidiabetics — In diabetic PVD: code Z79.4 (long-term insulin use) or Z79.84 (long-term use of oral hypoglycemic drugs); critical for E11.5x combo coding

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

The following guidelines from the FY2026 ICD-10-CM Official Guidelines for Coding and Reporting are most relevant to PVD risk adjustment coding:

Guideline I.C.9.a — Atherosclerosis of Extremities

Codes in I70.2–I70.7 are combination codes specifying vessel type, manifestation (claudication, rest pain, ulceration, gangrene), and often laterality. When a patient has atherosclerosis with more than one complication (e.g., rest pain AND ulceration), code the most severe manifestation per the tabular hierarchy: gangrene > ulceration > rest pain > claudication. Do not code a less severe manifestation if a more severe one is present.

Guideline I.C.9 — Hypertensive/Atherosclerotic Combination Codes

Atherosclerosis of the coronary arteries (I25.1xx) and peripheral arteries (I70.2xx) are independent combinations and should both be coded when present. PVD with hypertension does not create a mandatory combination code — each is coded separately.

Guideline I.C.4.a — Diabetes and Peripheral Vascular Complications

The ICD-10-CM convention “use additional code” at E11.51 and E11.52 instructs coders to add additional peripheral angiopathy codes to identify severity. The provider must document a causal relationship between the patient’s diabetes and the vascular disease to use E11.51/E11.52. When documentation says “PVD in a diabetic patient” without stating causation, query the provider. When documentation says “diabetic peripheral angiopathy” or “PVD due to diabetes,” the causal link is established.

Guideline I.C.9.b — CLTI / Critical Limb Ischemia (Effective FY2020, Active FY2026)

Per CMS/NCHS ICD-10-CM tabular updates, “chronic limb-threatening ischemia” and “critical limb ischemia” are included as “includes” notes under I70.22 (rest pain), I70.23, I70.24 (ulceration), and I70.26 (gangrene). When a provider documents CLTI or CLI, code the manifestation-specific I70.2xx code based on documented manifestation — there is no separate CLTI code.

Guideline I.C.9.c — Atherosclerosis with Post-Procedural Status

A patient who has undergone peripheral revascularization (bypass, PTA/stent) still carries the underlying atherosclerosis diagnosis. Code the appropriate I70.3xx–I70.7xx (for bypass graft) or residual I70.2xx (native artery) as applicable. Also assign Z95.828 (Presence of other vascular implants and grafts) for stents, and code the underlying atherosclerosis in grafts using the appropriate I70.3xx–I70.7xx category.

Guideline I.B.4 — Signs and Symptoms with Definitive Diagnoses

When a more definitive diagnosis is established, code the definitive diagnosis. Do not code ABI findings as a diagnosis code — the ABI supports the provider’s documented clinical diagnosis.

🔢 ICD-10-CM Code Set (FY2026)

All codes verified against the FY2026 ICD-10-CM Tabular List and CMS 2026 ICD-10-CM files.

HCC 263 Codes — Atherosclerosis with Ulceration or Gangrene (RF 1.118)

HCC 264 Codes — Vascular Disease with Complications (RF 0.455)

No V28 RAF Payment — Important Exclusions

Supporting / Additional Codes

🔎 Indexing

Use the FY2026 ICD-10-CM Alphabetic Index with the following main terms:

🏥 CPT (2026)

For detailed CPT coding of vascular surgery and endovascular procedures, see the companion comprehensive PVD CDG. Brief summary for risk adjustment context:

🧾 HCPCS (2026)

📚 AHA Coding Clinic (Recent Guidance)

💰 HCC / Risk Adjustment (v28)

CMS-HCC Model V28 is 100% operative for Medicare Advantage payment year 2026, per CMS 2026 Advance Notice. The following mapping table represents the complete PVD-relevant HCC structure under V28.

*RF = Relative Factor; community, non-dual, aged beneficiary. Source: CMS HCC V28 Tip Sheet / Patient Quality Alliance. †PMPM approximate, based on MA benchmark of ~$800/mo × RF; illustrative only.

RAF Revenue Impact of Code Specificity: Clinical Scenarios

V24 → V28 Transition: Key PVD Changes

Per DoctusTech V28 series analysis:

• V24 HCC 106 (Atherosclerosis with Ulceration/Gangrene) → V28 HCC 263: RF decreased by 0.426
• V24 HCC 107 (Vascular Disease with Complications) → split into V28 HCC 264, 267, 383
• Codes for atherosclerosis with rest pain moved to V28 HCC 264: RF increased by 0.218 vs V24 equivalent
• Atherosclerosis with claudication alone: removed from all payment HCCs in V28
• PVD + diabetes interaction factor: significantly reduced under V28 constraining rules

✍️ CDI Query Templates

All queries below are formatted per ACDIS CDI Query Practice Guidelines — non-leading, multiple-choice format with clinical indicators listed. These are compliant with AHIMA 2019 Practice Brief on Query Management.

Lost RAF Revenue Calculator — Per Missed Code

The table below illustrates annual revenue impact per missed PVD HCC code for a Medicare Advantage plan. Assumes average MA monthly benchmark of ~$950 (approximate; varies by county and Star rating). Per CMS 2026 MA rate notice:

🧑‍⚕️ Treatments (Clinical)

Clinical treatments are relevant to CDI because they provide MEAT documentation supporting active management of PVD:

Medical Management

• Supervised exercise therapy (SET) — 36-session supervised walking program; first-line for claudication per AHA/ACC PAD Guidelines; CPT 93668
• Risk factor modification — Statin therapy, antihypertensives, glycemic control, smoking cessation (document F17.2xx / Z72.0 + cessation counseling)
• Antiplatelet therapy — Clopidogrel preferred over aspirin alone in symptomatic PAD per AHA guidelines
• COMPASS regimen — Rivaroxaban 2.5 mg BID + aspirin 100 mg for high-risk symptomatic PAD; reduces MALE (major adverse limb events)
• Wound care for CLTI — Specialized wound care teams; WIfI staging guides treatment intensity; debridement, offloading, antimicrobial dressings

Interventional / Surgical

• Percutaneous transluminal angioplasty (PTA) with or without stenting — endovascular revascularization (CPT 37220–37235)
• Peripheral bypass surgery — Open revascularization for complex/multilevel disease (CPT 35556–35571)
• Atherectomy — Rotational, directional, or laser; used for calcified or long-segment disease (CPT 37225, 37226, 37229, 37230, 37233, 37234)
• Amputation — Minor (digit/transmetatarsal) or major (below-knee, above-knee) when limb not salvageable; document Z89.xxx status post amputation code
• Hyperbaric oxygen therapy (HBO) — HCPCS G0277; Medicare covers for diabetic wounds grade III+ after standard wound care failure

WIfI Staging — Wound, Ischemia, foot Infection

The Society for Vascular Surgery WIfI classification stratifies CLTI limb salvage risk using three components:

• Wound (W) — Grade 0 (no ulcer/minor gangrene) to Grade 3 (deep ulcer, extensive gangrene)
• Ischemia (I) — Grade 0 (ABI ≥0.8) to Grade 3 (ABI <0.4 / flat waveforms)
• foot Infection (fI) — IDSA classification Grade 0 (no infection) to Grade 3 (severe/limb-threatening)

WIfI grade drives urgency of revascularization and directly correlates with ICD-10-CM severity: WIfI Ischemia Grade 2–3 = I70.22x (rest pain) or I70.23x–I70.26x (ulcer/gangrene). Document WIfI score to support CLTI diagnosis specificity.

🎓 Patient Education / Summary

Key messages for patients with PVD in the Medicare Advantage context (relevant for care management documentation supporting MEAT):

• What is PVD / PAD? — Blockages in the blood vessels of your legs (and sometimes arms) caused by a buildup of fatty deposits (plaque) in the artery walls. Over time, these blockages reduce blood flow, causing leg pain and, in severe cases, non-healing wounds or gangrene.
• Why does accurate diagnosis matter? — Your care team uses specific codes to describe how severe your condition is. These codes help ensure your Medicare Advantage plan allocates the right level of resources for your care. It is important that your symptoms — especially nighttime foot pain, non-healing sores, or color changes in your foot — are reported to your doctor at every visit.
• What are the warning signs to report? — Call your doctor immediately if you develop: pain in your foot while resting or at night; a wound or sore on your foot or leg that is not healing after 2 weeks; your foot or toes turning dark, blue-black, or developing black tissue; sudden severe leg pain with numbness.
• Lifestyle modifications — Quit smoking (the single most important modifiable risk factor); walk daily (even short distances build collateral circulation); control blood sugar if diabetic; take prescribed blood thinners and cholesterol medications every day; inspect your feet daily for sores.
• Annual visits matter — Under Medicare Advantage, your annual wellness visit is important for managing your vascular disease. Bring a list of all symptoms, medications, and any wounds. This ensures your doctor can document and manage your complete condition each year.

For a comprehensive clinical overview including full anatomy, pathophysiology, and complete procedural coding, see the companion Peripheral Vascular Disease Clinical Documentation Guide at CCO.

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)